ARS Pharmaceuticals, Inc.
SPRY
$14.05
$0.816.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 86.58M | 2.07M | 500.00K | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 86.58M | 2.07M | 500.00K | -- | 0.00 |
| Cost of Revenue | 3.89M | 4.54M | 6.80M | 5.13M | 3.40M |
| Gross Profit | 82.69M | -2.47M | -6.30M | -5.13M | -3.40M |
| SG&A Expenses | 35.49M | 19.28M | 9.04M | 8.06M | 6.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.38M | 23.82M | 15.84M | 13.19M | 10.23M |
| Operating Income | 47.20M | -21.75M | -15.34M | -13.19M | -10.23M |
| Income Before Tax | 50.22M | -19.13M | -12.52M | -10.29M | -7.17M |
| Income Tax Expenses | 288.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | 49.93M | -19.13M | -12.52M | -10.29M | -7.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.93M | -19.13M | -12.52M | -10.29M | -7.17M |
| EBIT | 47.20M | -21.75M | -15.34M | -13.19M | -10.23M |
| EBITDA | 47.23M | -21.73M | -15.32M | -13.18M | -10.21M |
| EPS Basic | 0.51 | -0.20 | -0.13 | -0.11 | -0.07 |
| Normalized Basic EPS | 0.31 | -0.12 | -0.08 | -0.07 | -0.06 |
| EPS Diluted | 0.42 | -0.20 | -0.13 | -0.11 | -0.07 |
| Normalized Diluted EPS | 0.26 | -0.12 | -0.08 | -0.07 | -0.06 |
| Average Basic Shares Outstanding | 97.40M | 97.03M | 96.83M | 96.49M | 96.13M |
| Average Diluted Shares Outstanding | 119.21M | 97.03M | 96.83M | 96.49M | 96.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
